Modulation of Wnt–β-catenin signaling with antibodies: therapeutic opportunities and challenges
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Since the recognition that mutations in components of the Wnt-β-catenin pathway underlie some human cancers, considerable attention has been dedicated to developing therapeutic modalities to block its activity. Despite numerous efforts, no drug directly inhibiting Wnt signaling is currently clinically available. Conversely, activating the Wnt pathway in a specific manner has recently been made possible with new molecules mimicking the activity of Wnt proteins, thus offering new possibilities for controlling tissue stem cell activity and for the rational treatment of various degenerative conditions. We describe the landscape of antibody modalities that modulate the Wnt-β-catenin pathway, and detail the advances and challenges in both cancer and regenerative medicine drug development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Canonical wnt signaling in differentiated osteoblasts controls osteoclast differentiation.
Glass, D. A., Bialek, P., Ahn, J. D., Starbuck, M., Patel, M. S., Clevers, H., Taketo, M. M., Long, F., McMahon, A. P., Lang, R. A., et al. (2005) · Developmental Cell · doi:10.1016/j.devcel.2005.02.017 · Cited by 1,558
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis
Saag, K. G., Petersen, J., Brandi, M. L., Karaplis, A. C., Lorentzon, M., Thomas, T., Maddox, J., Fan, M., Meisner, P. D., & Grauer, A. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708322 · Cited by 1,544
Sclerostin Binds to LRP5/6 and Antagonizes Canonical Wnt Signaling
Li, X., Zhang, Y., Kang, H., Liu, W., Liu, P., Zhang, J., Harris, S. E., & Wu, D. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413274200 · Cited by 1,366
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
McClung, M. R., Grauer, A., Boonen, S., Bolognese, M. A., Brown, J. P., Diez-Perez, A., Langdahl, B. L., Reginster, J.-Y., Zanchetta, J. R., Wasserman, S. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1305224 · Cited by 1,258
Recurrent R-spondin fusions in colon cancer
Seshagiri, S., Stawiski, E. W., Durinck, S., Modrusan, Z., Storm, E. E., Conboy, C. B., Chaudhuri, S., Guan, Y., Janakiraman, V., Jaiswal, B. S., et al. (2012) · Nature · doi:10.1038/nature11282 · Cited by 960
SOST Is a Ligand for LRP5/LRP6 and a Wnt Signaling Inhibitor
Semënov, M., Tamai, K., & He, X. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504308200 · Cited by 771
Intestinal label-retaining cells are secretory precursors expressing Lgr5
Buczacki, S. J. A., Zecchini, H. I., Nicholson, A. M., Russell, R., Vermeulen, L., Kemp, R., & Winton, D. J. (2013) · Nature · doi:10.1038/nature11965 · Cited by 761
Visualization and targeting of LGR5+ human colon cancer stem cells
Shimokawa, M., Ohta, Y., Nishikori, S., Matano, M., Takano, A., Fujii, M., Date, S., Sugimoto, S., Kanai, T., & Sato, T. (2017) · Nature · doi:10.1038/nature22081 · Cited by 728
WNT/β-catenin pathway activation correlates with immune exclusion across human cancers
Luke, J. J., Bao, R., Sweis, R. F., Spranger, S., & Gajewski, T. F. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1942 · Cited by 722
The R-spondin/Lgr5/Rnf43 module: regulator of Wnt signal strength
de Lau, W., Peng, W. C., Gros, P., & Clevers, H. (2014) · Genes & Development · doi:10.1101/gad.235473.113 · Cited by 656
Cited by
Molecular basis of Wnt biogenesis, secretion, and Wnt7-specific signaling
Qi, X., Hu, Q., Elghobashi-Meinhardt, N., Long, T., Chen, H., & Li, X. (2023) · Cell · doi:10.1016/j.cell.2023.09.021 · Cited by 40
Liang, Y., Mei, Q., He, E., Ballar, P., Wei, C., Wang, Y., Dong, Y., Zhou, J., Tao, X., Qu, W., et al. (2024) · Cell Death & Disease · doi:10.1038/s41419-024-07069-8 · Cited by 9
Bruguera, E. S., Mahoney, J. P., & Weis, W. I. (2025) · eLife · doi:10.7554/elife.96743 · Cited by 9
Bruguera, E. S., Mahoney, J. P., & Weis, W. I. (2025) · eLife · doi:10.7554/elife.96743.3 · Cited by 2
Metadata
- Authors
- O'Brien, S., Chidiac, R., & Angers, S.
- Venue
- Trends in Pharmacological Sciences
- Publisher
- Elsevier BV
- Published
- 2023-06
- Volume
- 44
- Issue
- 6
- Pages
- 354-365
- ISSN
- 0165-6147 (ISSN-L)
- OpenAlex
- W4366372020
- Cited by
- 39
- References
- 18
- FWCI
- 0.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Modulation of Wnt–β-catenin signaling with antibodies: therapeutic opportunities and challenges. https://app.cochat.ai/papers/10.1016/j.tips.2023.03.008
- The paper
- O'Brien, S., Chidiac, R., & Angers, S. (2023). Modulation of Wnt–β-catenin signaling with antibodies: therapeutic opportunities and challenges. Trends in Pharmacological Sciences. https://doi.org/10.1016/j.tips.2023.03.008
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.